IP Library Granted Patent US 10,071,985
Granted Patent B2
US 10,071,985 · App. 15/680,041 · Granted Sep 11, 2018

Therapeutic compounds

Inventors: Michael Graupe (Pacifica, CA); Steven J. Henry (San Mateo, CA); John O. Link (San Francisco, CA); Charles William Rowe (San Bruno, CA); Roland D. Saito (San Mateo, CA); Scott D. Schroeder (Union City, CA); Dimitrios Stefanidis (Saratoga, CA); Winston C. Tse (Redwood City, CA); Jennifer R. Zhang (Union City, CA)
Assignee: Gilead Sciences, Inc.
C07D401/14A61K31/4439A61K31/537A61K31/675A61K31/7076A61K45/06C07C317/08C07D231/54C07F5/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,071,985
App. No.
15/680,041
Granted
Sep 11, 2018
Kind
B2
Abstract

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Claims (29)

1. A compound of Formula (Ia):

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is a compound of Formula (Ib)

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

4. A compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , which is a compound of Formula (IIb)

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 3 , wherein the composition is suitable for oral administration.

8. The pharmaceutical composition of claim 7 , wherein the composition is a capsule.

9. The pharmaceutical composition of claim 8 , wherein the capsule is a hard capsule.

10. The pharmaceutical composition of claim 8 , wherein the capsule is a soft capsule.

11. The pharmaceutical composition of claim 7 , wherein the composition comprises a dosage amount from 1 mg to 1000 mg.

12. The pharmaceutical composition of claim 11 , wherein the composition comprises a dosage amount from 10 mg to 50 mg.

13. The pharmaceutical composition of claim 11 , wherein the composition comprises a dosage amount from 50 mg to 300 mg.

14. The pharmaceutical composition of claim 11 , wherein the composition comprises a dosage amount from 300 mg to 1000 mg.

15. The compound of claim 2 , wherein the compound is an amorphous solid.

16. The pharmaceutical composition of claim 6 , wherein the composition is suitable for oral administration.

17. The pharmaceutical composition of claim 16 , wherein the composition is a capsule.

18. The pharmaceutical composition of claim 17 , wherein the capsule is a hard capsule.

19. The pharmaceutical composition of claim 17 , wherein the capsule is a soft capsule.

20. The pharmaceutical composition of claim 16 , wherein the composition comprises a dosage amount from 1 mg to 1000 mg.

21. The pharmaceutical composition of claim 20 , wherein the composition comprises a dosage amount from 10 mg to 50 mg.

22. The pharmaceutical composition of claim 20 , wherein the composition comprises a dosage amount from 50 mg to 300 mg.

23. The pharmaceutical composition of claim 20 , wherein the composition comprises a dosage amount from 300 mg to 1000 mg.

24. The compound of claim 5 , wherein the compound is a pharmaceutically acceptable salt.

25. The compound of claim 24 , wherein the compound is a trifluoroacetic acid salt.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2018
From: GRAUPE, MICHAEL; HENRY, STEVEN J.; LINK, JOHN O.; ROWE, CHARLES WILLIAM; SAITO, ROLAND D.; SCHROEDER, SCOTT D.; STEFANIDIS, DIMITRIOS; TSE, WINSTON C.; ZHANG, JENNIFER R.
To: GILEAD SCIENCES, INC.
Reel/Frame 047709/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2017
From: GRAUPE, MICHAEL; HENRY, STEVEN J.; LINK, JOHN O.; ROWE, CHARLES WILLIAM; SAITO, ROLAND D.; SCHROEDER, SCOTT D.; STEFANIDIS, DIMITRIOS; TSE, WINSTON C.; ZHANG, JENNIFER R.
To: GILEAD SCIENCES, INC.
Reel/Frame 043352/0680 →
Continuity (3)
Provisional Application 62457555 · Feb 10, 2017
Provisional Application 62377312 · Aug 19, 2016
Related Publication 20180051005A1 · Feb 22, 2018
Cited By (7)
US 12,187,753 US 12,246,022 US 12,257,264 US 12,404,262 US 12,492,189 US 12,594,267 US 12,636,279